• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Urology >An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
【24h】

An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.

机译：用于治疗勃起功能障碍的新型口服PDE5抑制剂的更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The management of erectile dysfunction (ED) has been revolutionized by the discovery of phosphodiesterase 5 (PDE5) inhibitors, which have been commercially available for more than a decade and are the first-line therapeutic option for men with ED. Sildenafil, vardenafil and tadalafil were approved by the European Medicine Agency and the US FDA for the treatment of ED on the back of their high efficacy rates and favorable safety profiles. However, despite the fact that more than 50 million patients with ED worldwide have been successfully treated with one of these PDE5 inhibitors, some men--most notably those with severe neurologic damage, diabetes mellitus or severe vascular disease--are resistant to the currently available drugs and require more-invasive treatments, such as intracavernosal injection therapy. Partly as a consequence of this, research into alternative therapeutic approaches continues, including the development of new PDE5 inhibitors, centrally acting pharmaceutical agents, and application of molecular technologies such as gene therapy and stem cell therapy.
机译：磷酸二酯酶5（PDE5）抑制剂的发现已经彻底革新了勃起功能障碍（ED）的管理方法，磷酸二酯酶5（PDE5）抑制剂已经在市场上销售了十多年，是患有ED的男性的一线治疗选择。西地那非，伐地那非和他达拉非因其高效率和良好的安全性而被欧洲医学机构和美国FDA批准用于治疗ED。然而，尽管事实是全世界已经有超过5000万的ED患者使用这些PDE5抑制剂之一成功治疗，但仍有一些男性，尤其是那些患有严重神经系统疾病，糖尿病或严重血管疾病的男性，对目前的抗药性现有药物，需要更具侵入性的治疗方法，例如海绵体腔内注射治疗。因此，继续进行替代治疗方法的研究，包括开发新的PDE5抑制剂，中枢作用药物以及分子技术（例如基因治疗和干细胞治疗）的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号